Follow-on drug yields positive bioequivalence results

07/11/2008 | Reuters

A 32-patient trial showed that INS-19, an experimental drug designed by Insmed to boost white blood cells, demonstrated equivalence with Amgen's Neupogen. Insmed plans to meet with the FDA to talk about a late-stage trial and thinks it is the first U.S. firm to report human-bioequivalence data for a follow-on biologic.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY